J
Jean-Paul Nicolas
Researcher at University of Paris
Publications - 27
Citations - 1803
Jean-Paul Nicolas is an academic researcher from University of Paris. The author has contributed to research in topics: Receptor & Agonist. The author has an hindex of 18, co-authored 27 publications receiving 1727 citations.
Papers
More filters
Journal ArticleDOI
Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat
Alain P. Gobert,Jean-Michel Rivet,Françoise Lejeune,Adrian Newman-Tancredi,Agnes Adhumeau‐Auclair,Jean-Paul Nicolas,Laetitia Cistarelli,Christophe Melon,Millan Mark +8 more
TL;DR: 5‐HT2C receptors exert a tonic, suppressive influence on the activity of mesocortical — as well as mesolimbic and nigrostriatal — dopaminergic pathways, likely via indirect actions expressed at the level of their cell bodies.
Journal ArticleDOI
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Millan Mark,Adrian Newman-Tancredi,Valérie Audinot,Didier Cussac,Françoise Lejeune,Jean-Paul Nicolas,Francis Cogé,Jean-Pierre Galizzi,Jean A. Boutin,Jean-Michel Rivet,Anne Dekeyne,Alain Gobert +11 more
TL;DR: The α2‐AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association with fluoxetine, whereas fluparoxan selectively enhances hippocampal noradrenaline (NAD) turnover and enhances striatal dopamine turnover and suppresses striatal turnover of 5‐HT.
Journal ArticleDOI
Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2 .
Olivier Nosjean,Jean-Paul Nicolas,Frederique Klupsch,Philippe Delagrange,Emmanuel Canet,Jean A. Boutin +5 more
TL;DR: New experimental conditions for the pharmacological study of melatonin-sensitive QR2 isoforms are details and it is suggested that, in addition to an already demonstrated inter-species difference, inter-tissues differences in QR2 sensitivity to melatonin may exist in primates.
Journal ArticleDOI
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
Adrian Newman-Tancredi,Didier Cussac,Valérie Audinot,Jean-Paul Nicolas,Frédéric De Ceuninck,Jean-A. Boutin,Millan Mark +6 more
TL;DR: In conclusion, antiparkinson agents display diverse agonist and antagonist properties at multiple subtypes of D2-like receptor and α1/α2-AR, actions, which likely contribute to their contrasting functional profiles.
Journal ArticleDOI
Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.
M.J. Millan,Alain Gobert,J. ‐M. Rivet,A. Adhumeau-Auclair,Cussac Didier,Adrian Newman-Tancredi,A. Dekeyne,Jean-Paul Nicolas,Françoise Lejeune +8 more
TL;DR: In contrast to citalopram, mirtazapine reinforces frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission, and reflects antagonist properties at α2A‐AR and 5‐HT2C receptors.